Citadel Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Citadel Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,600	Closed	-$80.1K	–	14763
2024 Q3	$80.1K	Buy	8,600 +2,700	+46%	+$19.6K	﹤0.01%	11409
2024 Q2	$33.9K	Sell	5,900 -1,700	-22%	-$10.1K	﹤0.01%	12151
2024 Q1	$51K	Buy	+7,600	New	+$42.2K	﹤0.01%	12158
2023 Q2	–	Sell	-500	Closed	-$3.1K	–	14599
2023 Q1	$3.1K	Sell	500 -39,000	-99%	-$255K	﹤0.01%	14071
2022 Q4	$252K	Buy	39,500 +1,300	+3%	+$9.8K	﹤0.01%	9683
2022 Q3	$328K	Buy	+38,200	New	+$492K	﹤0.01%	9363

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citadel Advisors's FHTX Position: Q1 2026 in Review

Citadel Advisors increased its Foghorn Therapeutics (FHTX) stake by 9.7% in Q1 2026, buying an estimated $97.4K and bringing the position to 200,013 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #7755.

Citadel Advisors first reported a position in FHTX in Q1 2022 and has held it in 10 quarters since. The position peaked at $984K in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

Citadel Advisors held 200,013 shares of Foghorn Therapeutics worth $956K as of Q1 2026.
Citadel Advisors bought 17,737 Foghorn Therapeutics shares in Q1 2026, an estimated $97.4K.
Foghorn Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7755 holding.
Citadel Advisors first reported a position in Foghorn Therapeutics in Q1 2022 and has held it in 10 quarters since.
Citadel Advisors's Foghorn Therapeutics position peaked at $984K in Q4 2025.
105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.